A narrative summary of selected presentations that took place on 11th−12th May 2017, as part of the Encuentro Latinoamericano de Infecciones Respiratorias Recurrentes (ELAIR) educational event in Mexico City, Mexico
Speakers: Manuel E. Soto-Martínez,1 José Antonio Ortega Martell,2 Marcus H. Jones3
1. Pediatric Pulmonologist, Hospital Nacional de Niños, Universidad de Costa Rica, San José, Costa Rica
2. Autonomous University of Hidalgo State, Pachuca, Mexico
3. Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil
Disclosure: The authors received an honorarium from OM/Vifor Pharma as regional experts and presenters at the ELAIR summit in Mexico. Prof Soto-Martínez is a speaker for Merck, GlaxoSmithKline, AstraZeneca, Pfizer, Sanofi, Abbott, and OM/Vifor Pharma. Prof Jones has received grant research support from AstraZeneca, GlaxoSmithKline, and Abbvie, as well as honoraria or consultation fees from AstraZeneca, GlaxoSmithKline, Abbvie, and OM/Vifor Pharma.
Acknowledgements: Writing assistance was provided by Ewen Legg, Halcyon Medical Writing, Thurso, UK.
Support: The publication of this article was funded by OM/Vifor Pharma. The views and opinions expressed are those of the authors and not necessarily those of OM/Vifor Pharma.
Citation: EMJ Respir. 2017;[Suppl 14]:29-42.
The third Encuentro Latinoamericano de Infecciones Respiratorias Recurrentes (ELAIR) took place in Mexico City, Mexico, on 11th−12th May 2017. ELAIR brought together experts from across Latin America and further afield, continuing an extraordinary didactic exercise on the cutting-edge advances of respiratory medicine. Impressive progress has been made in the past 15 years, with new treatments available to manage and prevent airway infections. It remains to be seen how this might affect the related conditions of wheezing and asthma in predisposed and sensitised subjects. However, early data suggest that lower respiratory infection rates may reduce the development of the above conditions which are closely related to viral infections. Immunomodulators that both prime the immune system to fight infection and reduce inflammation are likely to play a major role in secondary and even potentially primary prevention of atopic diseases.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.